Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855856 | 1.00 | TRIM24 (0.38) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL23687397 | 0.93 | — | — | |
| SCHEMBL857656 | 0.93 | — | — | |
| SCHEMBL725114 | 0.93 | — | — | |
| SCHEMBL18922082 | 0.86 | — | — | |
| SCHEMBL2068452 | 0.86 | — | — | |
| SCHEMBL20049585 | 0.86 | — | — | |
| SCHEMBL7947709 | 0.80 | TRIM24 (0.39) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL7942803 | 0.78 | TRIM24 (0.42) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL2068418 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2024-08-06 | — | — | US | disclosed |
| EP-3852747-B1 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3852747-B1 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220041572-A1 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-10 | — | — | US | disclosed |
| CN-109415387-B | Arginase inhibitors and therapeutic uses thereof | 昂科艾伦迪治疗法公司 | 2021-08-27 | — | — | CN | disclosed |
| EP-3852747-A1 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-112702998-A | Cycloheptanoic acids as LPA antagonists | 百时美施贵宝公司 | 2021-04-23 | — | — | CN | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| EP-3452485-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2020-09-09 | — | — | EP | disclosed |
| WO-2017191130-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017191130-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2017-11-09 | — | — | WO | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | TRIM24 4023/4885TRIM33 4743/4885ALDH1A1 3395/4885 |
| US-20220041572-A1 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR5 | TRIM24 4226/4885TRIM33 4745/4885ALDH1A1 1734/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | TRIM24 4097/4885TRIM33 4793/4885ALDH1A1 3533/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | TRIM24 3963/4885TRIM33 4734/4885ALDH1A1 3049/4885 |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | TRIM24 2896/4885TRIM33 2610/4885ALDH1A1 675/4885 |
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | TRIM24 2896/4885TRIM33 2610/4885ALDH1A1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.